SEC Form 4													
FORM 4) STAT	ES S	SECURITIES Washingt			MMIS	SION	ROVAL					
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).		pursuar	T CHANGES nt to Section 16(a) of ction 30(h) of the Im	of the Se	ecuriti	es Exchange A							
1. Name and Address of Reporting Perso Dananberg Jamie		2. Issuer Name and Ticker or Trading Symbol <u>Unity Biotechnology, Inc.</u> [UBX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below)				
(Last) (First) C/O UNITY BIOTECHNOLOGY 285 EAST GRAND AVENUE		3. Date of Earliest Transaction (Month/Day/Year) 03/30/2020							Chief Medical Officer				
Street) SOUTH SAN FRANCISCO				nendment, Date of	Original	Filed	(Month/Day/Ye	6. Indi Line) X	,				
(City) (State)	(Zip)												
Т	able I - Nor	n-Deriva	tive S	ecurities Acq	uired,	Dis	posed of, o	r Bene	ficially	Owned			
			tion ty/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			5. Amount of Securities Beneficially Owned Follow	6. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4)	of Indirect Beneficial Ownership	
					Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock, \$0.0001 par value 03/3			2020		A		24,255 ⁽¹⁾	A	\$0.00	454,702 ⁽⁾	²⁾ D		
	Table II - I	Derivati	ve Se	curities Acqui	red, C	Dispo	osed of, or	Benefi	cially C	Owned			

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$5.95	03/30/2020		A		98,490		(3)	03/29/2030	Common Stock	98,490	\$0.00	98,490	D	

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") which vest in equal annual installments over a three year period measured from March 30, 2020. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

2. Includes RSUs which vest over time measured from the grant date.

3. Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on March 30, 2020 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

Remarks:

<u>/s/ Tamara L. Tompkins,</u> <u>Attorney-in-Fact for Jamie</u> <u>Dananberg</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

** Signature of Reporting Person Date

04/01/2020